Table 2.
Characteristics of studies included in the meta-analysis.
| Author, Year |
Oral Cavity Subsite | Number of Patients | Accrual Period | Types of Minor Pathological Risk Factors | Presence of Major Pathological Risk Factor | Number of Patients in CRT Arm/Total | Median FU (Months) | Disease-Free Survival (DFS) | Local Recurrence-Free Survival (LRFS) | Overall Survival (OS) |
|---|---|---|---|---|---|---|---|---|---|---|
| Spiotto M. (2017) [76] |
Oral tongue | 2803 | 2004–2012 | LVI, DOI ≥ 5 mm, pT3 or pT4, multiple lymph nodes without ENE | No | 1308/2803 | 33 | / | / | 73.3% HR: 0.78 (95%CI: 0.64–0.96) |
| Trifiletti (2017) [77] |
Oral cavity and other H and N sites (oropharynx, larynx, etc.) | 5094/10870 (2899 RT, 2195 CTRT) | 2004–2012 | Positive node at level IV or V, multiple lymph nodes without ENE | No | 2195/10870 | 38,4 | / | / | 3 y OS: 74.2% 5 y OS: 65.3% HR: 0.902 (95%CI: 0.861 to 0.944) |
| Chen W.C. (2016) [78] |
OSCC | 567 | 2002–2013 | PNI, LVI, DOI ≥ 5 mm (10 mm), close margin (< 2–5 mm), pT3 or pT4, multiple lymph nodes without ENE | 1 (positive margins in 28 patients, ENE 83 patients) | 127/567 | 42 | 50.2% HR: 0.38 (95%CI: 0.21–0.68) |
74.5% HR: 0.33 (95%CI: 0.14–0.78) |
59.8% HR: 0.37 (95%CI: 0.19–0.72) |
| Fan K.H. (2017) [79] |
Buccal mucosa, tongue, gums, retromolar trigon, mouth floor, hard palate | 68 of 109 initially selected (34 CRT, 34 RT) | 1999–2009 | PNI, LVI, DOI ≥ 5 mm, close margin (<2–5 mm), pT3 or pT4 | No | 34/68 | 86.4 | 75.4% | 75.4% HR: 0.248 (95%CI: 0.103–0.596) |
67.2% HR: 0.426 (95%CI: 0.212–0.858) |
| Feng (2017) [80] |
Tongue, gingiva, buccal mucosa, mouth floor, hard palate | 809 (14% oropharynx) | / | PNI, LVI, pT3, or pT4, multiple lymph nodes without ENE | Yes, ENE + | 114/809 | Not reported | 51.4% | / | / |
| Chen M.M. (2018) [81] |
Lips, oral cavity | 5319 total H and N patients. Oral cavity: pRT group 1571, pCRT 956 | 2010–2013 | LVI, pT3, or pT4, multiple lymph nodes without ENE | No | 956/1571 | Not reported | / | / | For T1–4 N2–3, HR: 0.73 (95%CI: 0.58–0.93). For T3–4 N0–1, HR: 0.92 (95%CI: 0.71–1.19) |
| Fan K.H. (2014) [82] |
Tongue, buccal mucosa, gums, retromolar trigone, mouth floor, hard palate, lips | 138 | 1998–2008 | PNI, LVI, DOI ≥ 5 mm, close margin (<2–5 mm), positive nodes level IV or V | No | 77/138 | 35 | 60% | 70% | 60% |
| Li R. (2020) [75] |
Tongue, gingiva, buccal mucosa, mouth floor, retromolar trigone, palate, lip | 91 | 2016–2018 | pT3 or pT4, multiple lymph nodes without ENE | Yes, positive margins and ENE + | 91/91 | 24 | 75.3% (95%CI: 65.7–84.2%) | 79.0% | 82.4% (95%CI, 73.0–89.6%) |
| Patel (2021) [83] |
Retromolar trigone, gum, cheek mucosa, mouth floor and NOS, tongue, vestibule, lip | 1338 | 2004–2017 | pT3 or pT4 | Yes, positive margins and ENE + | 163/1338 (the other 23 patients received neoadjuvant CT then surgery +RT) |
24 | / | / | 64.6% |
| Osborn (2018) [84] |
OCSCC | 2303 | 2004–2012 | pT3 or pT4 | Yes, positive margins and ENE + | 1381/2303 | 47,7 | / | / | 67.4% |
| Lin C (2019) [85] |
OCSCC | 1200 | 2004–2016 | pT4, DOI > 5 mm (5 mm), positive nodes level IV or V, PNI, LVI | Yes, positive margins and ENE + | 411/1200 | 61 | 75% | / | 83% |
| Tasoulas (2021) [86] |
OCSCC | 616, 167 for OC | 2002–2006 | LVI, PNI, T3 or T4, multiple lymph nodes without ENE | Yes, ENE + | 92/616 45 high-risk patients |
Not reported | / | / | HR: 0.30 (95%CI: 0.15–0.61) for high-risk patients |